Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic gamma-delta T-cell infusion in advanced cancer
ChiCTR2400086398Phase 2Completed
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic gamma-delta T cells in cancer, sponsored by Shenzhen Second People's Hospital. Primary endpoints: Immune function check and Quality of life. Started Jul 2024; status: completed.
02
Drugs
allogeneic gamma-delta T cells
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2400086398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086398.